year-to-date very Hello, our of thanks delivering Thank teams, Giovanni. this global you, by quarterly I’m everyone. pandemic. strong in joining very our And while pleased operating results and again call execution the for today.
our discuss top slide line performance. turn to nine Let’s and
versus year execution, Third growing quarter a and our X% pro revenues on reflect strong continued prior year-to-date basis. forma to
can growth. robust our you As a see, demonstrated vast majority brands of
our with our of brands key year. me Eliquis underlying XX performance growth be and demonstrates the Starting strong U.S. teams to on provide best-in-class profile of continue double demand This commentary prior additional let execution our XX% in launches. robust digit Now, new the on with brands. TRx slide trends of versus and
you year, in coverage be expectations the larger discussed the per it, of enter should component previously, gap related this which increased to as component we This our XXXX As we coverage more our with of size to is Medicare our This half gap net QX. pronounced second a line liability impact expect affects accrue results. patient gross as this to for our was and a the mix. sales in is And and to increasing a in its U.S. strength Eliquis, including outlook $X prior we XX% the the strong one internationally, in within many revenue approximately France, Both, billion, the with for growing the United Eliquis the of class. enabling number NOAC of remained growth from quarter. Internationally, globally, in Germany, see factor markets be and very continues growing continue profile, share strong to Kingdom. versus year. resulting fourth patients
in teams been the on well. U.S., executing have to Turning slide XX, very Opdivo
growing XLA. We And that by benefiting of buying approximately X% for shares X%. What underlying you in lungs is more Opdivo. return the versus continue favorable and strong see we’re share have approvals reflected the encouraged across to see key We really underlying acceleration customer QX as QX high-single-digit Underlying demand, sequential to to indications. grew can with first-line Sales was two, in growth cancer XXX quarter the as well demand Yervoy. driven of growth the from first-line patterns. adoption the from now lung patients by
Japanese We patterns to board the in Opdivo across these quarter, Internationally, impact primarily return X% versus and the sales and a new in reimbursement gain markets, saw RCC European melanoma. rebound as markets seen demand in supporting expect the strong to commercial with from stronger growth fourth growth demand, a for the up to continue, for reverse year. sequential continued indications annual to by execution to driven prior XXXX. but Sequentially, year-over-year first-line buying our we’ve the we
lung this melanoma, new patient generally Yervoy chemotherapy starts some also tumors, be forward good the we the most in and of limited recovery quarter. to to continues in saw look impact first-line QX. Opdivo there Europe COVID in across While bringing of notably to softness patients we And in plus cancer but
things plus cancer, promise annual we confident Opdivo shows both makes several first-line invasive priority which clinically, for launches such and were To a look near-term us forward, more and which the first-line several XXXX, Opdivo have even sum As our bladder the esophageal teams expectations we year-over-year continued we the for indications in granted muscle Yervoy commercially as growth for executed and and gastric including expect and up, additional RCC in the potential review. and XXXX. adjutant well, Cabo in for in
starts. portfolio Pomalyst XX, new while longer being and Revlimid perform to experienced our which patients. in-line to This grew pro the this forma a and now XX%, treatment duration. recovering. Pomalyst of Moving patient well based earlier increased to Revlimid lines duration with use a strong treatment XX%, was In sales treatment forma therapies temporary better basis. driven pro XX%, impact myeloma offset softness for existing had in increased driven Revlimid a on double COVID increased in And duration. from markets. growth by on continue forma multiple on Pomalyst European XX%. on ex-U.S. small by we of and is performance digit and very major brand And COVID, primarily increased treatment, the share slide increased to growth grew U.S., strong some impact of on therapy for adherence observed pro by in driven new with for minimal patient is sales triplet ex-U.S. duration ongoing treatment
We are patients strong patterns. of new seeing to signs prior returning treatment
moving robust brand. over quarter U.S. two. $XX launches Global to off of on sales has awareness been were positive of the to feedback RS-positive anemia. the million, Now, recent representing In with MDS-associated slide XX% the significant the with physician quarter approval on remains XX. Reblozyl our growth a start in sequential
still new patient on the patients retention of the the pleased including patient be product the we While to and early, with treatment. to adhere launch, majority that continue with uptake
initial for recent the remained well although MDS-associated demand encouraged the the beta a very by reminder, product waiting with are proportion launches We underlying new and going early patients Germany Austria well, option. for of early Internationally, a uptake as in anemia. significant As patients in very bolus driven a by in launch. as the of treatment thalassemia is
also receive in we beta XXXX, thalassemia globally in of reimbursement. We Canada over markets look received to the forward approval associated and various launching course anemia for as
Turning to few seeing what through by encouraged the launch. we’re months we’re first Zeposia’s of Zeposia,
as and We’re focused driving sclerosis. on demand Zeposia SXP leading multiple the establishing modulator in
and teams executing our have commercial are strong We well. commercial secured access
the thus receptivity with initiation prescription physician pleased are seen we’ve and We far.
for approval newest the on September Onureg, granted to FDA, our moving by Xst. which AML maintenance Now, first-line launch, is on
maintenance and in approved the FDA in maintenance like it the This expect the has the were a physicians for a The the from of is that first will to While no there Europe feedback with for as resonating Onureg, educate new medicines with many And review that largely route demonstrates market setting setting is after prescribers use medicine launch, promising. administration chemotherapy. in intensive setting, in XXXX. in about previously well. oral of time some underdeveloped, patients. other message options overall MMA the patients under in and is approval maintenance is treatment take convenient early only very been survival
moving capital on slide to allocation Now, our balance XX. sheet and on
generate with third quarter Otezla. large cash with to cash $X.X on billion We marketable billion strong the from flow a approximately payments We including debt approximately gain continued of the for and in tax significant in $XX after securities. ended Thus operations in the quarter. payments, amount and tax cash payment liquidity position associated paid down is
Our half EBITDA and ratio, capital a than achieving less end debt the by one allocation priorities remain XXXX. to now and unchanged. which times is expected of Delevering
through against dividend priority. our we not have activity, our continued business our and innovation We development. To on commitment discussed, business in touch to development raised as investing future Giovanni our
MyoKardia. well of as for third Each and acquisition scientifically these strategically quarter, recently financially aligned, We including Forbius, with our our transactions agreement pending as in with is license of announced have sound deals executed over acquisition Dragonfly, line our attractive. development, criteria business of some important the
be We development, to strengthen for shareholders. long-term growth of will for and value additional to active for searching continue business the the in further our creating profile opportunities company
to XX. year-to-date, results our Now, updating XXXX let’s the strength we’re guidance of full-year on Based outlook. turn on our slide
year-to-date. range. between are to of billion the sales at upon revenue the $XX end performance and based higher expect the billion, $XX.X range narrowing we We to be do strong our And
operating to Turning expenses.
We total do our spend in be line have related and in MS&A slight some shifts generally spend our expectations. expect We R&D to lines. to with
expect $X.X business the one-time close advertising the our full tracking being time, taking very-pleased additional our $X.X out by We and same be the accelerating approximately decided mentioned, Giovanni now expect the increasing R&D as to and original remain to rate year, approximately expense, support full-year we with be together, EPS adjusted DTC now expected for to our we ahead capture, year. we $X.XX share. of now be between billion. tax approximately offset we synergy which, our are MS&A, all as billion. For is to spend such This make this to is per At XX% lower expectations. range we And $X.XX as investments, to
guidance takes in some the continues well mentioned brands. hole, to as the which Eliquis I affect fourth competitive account associated Our of with earlier, into as donut revenue established dynamics as continued quarter, our
reaffirming EPS associated $X.XX during forward our relates which guidance look XXXX guidance, we to on more absorbs our acquisition. as $X.XX, normally it we Now, as are to MyoKardia providing We dilution the our call, of color do. non-GAAP with to the XXXX, fourth quarter
I Q&A. our turn for for and want allow for Before the year-to-date. results results These over now we question-and-answer, around confident to world back Company. in of long-term move to remain Tim the thank the I’ll Giovanni outstanding teams me outlook the to such to call all delivering
